<DOC>
	<DOCNO>NCT02777788</DOCNO>
	<brief_summary>The purpose study observe efficacy chemotherapy combine Chinese patent drug patient advance non-small-cell lung cancer , also evaluate adverse reaction reliability .</brief_summary>
	<brief_title>Curative Study Chinese Traditional Medicine Treat Lung Cancer</brief_title>
	<detailed_description>Lung cancer common malignant tumor world 80 % -85 % non small cell lung cancer . The investigator perform multi-center , randomize , control , prospective study patient advance NSCLC . Patients randomize observational group ( Chinese patent drug plus chemotherapy ) , control group ( chemotherapy ) . The investigator observe 2 cycle regular follow-up arrange . The primary end point : Objective response rate ; The secondary end point : 1. progression-free survival ( PFS ) ; 2. overall survival ( OS ) ; 3 . Time Progression ( TTP ) ; 4. quality life questionnaire（QOL ) ; 5. end point : Toxicity , side effect security treatment assess time . The investigator expect integrate TCM combine chemotherapy well efficacy enhance Objective response rate，prolonging PFS , OS , improve QOL , reduce adverse reaction patient chemotherapy.Therefore study provide evidence optimize promote integrate TCM combine Western Medicine treatment .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nedaplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Pathologically cytologically confirm stage ⅢbⅣ NSCLC 2 . Ages Eligible Study : 1865 year old ; 3 . Physical status score ( ECOG PS ) ≤ 2 scores； 4 . Estimated life expectancy least 6 months； 5 . Participants major organ dysfunction chemotherapy contraindication : hemoglobin ≥10g/dL , absolute neutrophil count ( ANC ) ≥1.5*109/L , platelet ≥80*109/L , Liver kidney function normal ; 6 . Informed consent patient . 1 . Patient malignant tumor except NSCLC 5 year previous study entry . 2 . Patients receive targeted drug treatment； 3 . Serious problem heart , liver kidney severe dysfunction ; 4 . Pregnant child breast feeding woman ; 5 . Mental cognitive disorder ; 6 . Participating drug trial ; 7. Who allergic study drug . 8 . Diabetic patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Chinese Traditional Medicine</keyword>
</DOC>